Drug Profile
HTI 2088
Latest Information Update: 28 Mar 2020
Price :
$50
*
At a glance
- Originator Hengrui Therapeutics
- Class Antihyperglycaemics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Diabetes mellitus
Most Recent Events
- 28 Mar 2020 No recent reports of development identified for phase-I development in Diabetes-mellitus(In volunteers) in USA (PO, Tablet)
- 23 Oct 2017 Hengrui Therapeutics completes a phase I trial in Diabetes mellitus (In volunteers) in USA (PO) (NCT03203811)
- 17 Feb 2017 Phase-I clinical trials in Diabetes mellitus (In volunteers) in USA (PO) (NCT03203811)